Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis.

Wollmann BM, Syversen SW, Vistnes M, Lie E, Mehus LL, Molden E.

Drug Metab Dispos. 2018 Oct;46(10):1384-1389. doi: 10.1124/dmd.118.082065. Epub 2018 Jul 10.

PMID:
29991576
2.

4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.

Wollmann BM, Syversen SW, Lie E, Gjestad C, Mehus LL, Olsen IC, Molden E.

Clin Transl Sci. 2017 Jan;10(1):42-49. doi: 10.1111/cts.12431. Epub 2016 Nov 5.

3.

FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibody-positive rheumatoid arthritis and with radiographic progression.

Maehlen MT, Nordang GB, Syversen SW, van der Heijde DM, Kvien TK, Uhlig T, Lie BA.

J Rheumatol. 2011 Nov;38(11):2329-35. doi: 10.3899/jrheum.110489. Epub 2011 Sep 1.

PMID:
21885492
4.

Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis.

Scherer HU, van der Woude D, Willemze A, Trouw LA, Knevel R, Syversen SW, van der Linden MP, Lie B, Huizinga TW, van der Heijde DM, van der Helm-van Mil AH, Kvien TK, Toes RE.

Ann Rheum Dis. 2011 Aug;70(8):1461-4. doi: 10.1136/ard.2010.146506. Epub 2011 Jun 10.

PMID:
21666230
5.

Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis.

Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, van Der Heijde D, Kvien TK, Standal T.

Arthritis Rheum. 2011 Mar;63(3):662-9. doi: 10.1002/art.30163.

6.

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis.

van der Woude D, Syversen SW, van der Voort EI, Verpoort KN, Goll GL, van der Linden MP, van der Helm-van Mil AH, van der Heijde DM, Huizinga TW, Kvien TK, Toes RE.

Ann Rheum Dis. 2010 Jun;69(6):1110-6. doi: 10.1136/ard.2009.116384. Epub 2010 May 3.

PMID:
20439289
7.

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs.

Syversen SW, Haavardsholm EA, Bøyesen P, Goll GL, Okkenhaug C, Gaarder PI, van der Heijde D, Kvien TK.

Ann Rheum Dis. 2010 May;69(5):845-50. doi: 10.1136/ard.2009.122325. Epub 2010 Mar 16.

PMID:
20233753
8.

Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.

Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D.

J Rheumatol. 2009 Aug;36(8):1792-9. doi: 10.3899/jrheum090347.

PMID:
19671814
9.

Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.

Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D.

J Rheumatol. 2009 Aug;36(8):1785-91. doi: 10.3899/jrheum.090346.

PMID:
19671813
10.

Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers.

Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP.

J Rheumatol. 2009 Aug;36(8):1769-84. doi: 10.3899/jrheum.090262. Review.

PMID:
19671812
11.

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.

Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, Uhlig T, Gaarder PI, Kvien TK.

Ann Rheum Dis. 2010 Feb;69(2):345-51. doi: 10.1136/ard.2009.113092. Epub 2009 Jul 30.

PMID:
19648126
12.

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Bøyesen P, Hoff M, Odegård S, Haugeberg G, Syversen SW, Gaarder PI, Okkenhaug C, Kvien TK.

Arthritis Res Ther. 2009;11(4):R103. doi: 10.1186/ar2749. Epub 2009 Jul 1.

13.

Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.

Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, Haavardsholm EA, Kvien TK.

J Rheumatol. 2009 Feb;36(2):266-72. doi: 10.3899/jrheum.080180.

PMID:
19132792
14.

Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.

Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK.

Ann Rheum Dis. 2010 Jan;69(1):150-4. doi: 10.1136/ard.2008.103739.

PMID:
19095696
15.

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients.

Syversen SW, Goll GL, Haavardsholm EA, Bøyesen P, Lea T, Kvien TK.

Arthritis Res Ther. 2008;10(2):R28. doi: 10.1186/ar2381. Epub 2008 Mar 2.

16.

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, Kvien TK.

Ann Rheum Dis. 2008 Feb;67(2):212-7. Epub 2007 May 25.

PMID:
17526555
17.

Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.

Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP.

J Rheumatol. 2007 Mar;34(3):623-33. Review.

PMID:
17343310

Supplemental Content

Loading ...
Support Center